Current Report Filing (8-k)
October 15 2020 - 9:59AM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities
Exchange Act of 1934
Date of Report (Date of earliest event reported):
October 14, 2020
RASNA THERAPEUTICS, INC.
(Exact Name of Registrant as Specified in Charter)
|
Nevada
|
|
333- 191083
|
|
39-2080103
|
|
(State or other jurisdiction
of incorporation)
|
|
(Commission File Number)
|
|
(IRS Employer Identification No.)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
420 Lexington Avenue, Suite 2525,
New York, NY
|
|
10170
|
|
(Address of principal executive offices)
|
|
(Zip Code)
|
Registrant’s telephone number, including
area code: 646-396-4087
(Former name or former address, if changed
since last report)
Copies to:
Jeffrey Fessler, Esq.
Sheppard, Mullin, Richter & Hampton LLP
30 Rockefeller Plaza
New York, New York 10112
Telephone: (212) 653-8700
Facsimile: (212) 653-8701
Check the appropriate box below if the Form 8-K filing is intended
to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
o Written
communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
o Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
o Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
o Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Indicate
by check mark whether the registrant is an emerging growth company as defined in as defined in Rule 405 of the Securities
Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this
chapter). Emerging growth company o
If an emerging
growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with
any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. o
|
Item 5.02
|
Departure of Directors or Certain Officers; Election of Directors;
Appointment of Certain Officers;
Compensatory Arrangements of Certain Officers.
|
On October 15, 2020, the Board of Directors
of Rasna Therapeutics, Inc. (the “Company”) appointed Willy Simon as Chairman of the Company. Mr. Simon replaces Alessandro
Padova who resigned on October 14, 2020 for personal reasons. A press release announcing the appointment of Mr. Simon and the resignation
of Mr. Padova is attached as Exhibit 99.1 hereto and incorporated herein by reference.
|
|
Item 9.01
|
Financial Statements and Exhibit.
|
SIGNATURES
Pursuant to the requirements
of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned
thereunto duly authorized.
Date: October 15, 2020
|
|
RASNA THERAPEUTICS, INC.
|
|
|
|
|
|
|
|
|
By:
|
/s/ Keeren Shah
|
|
|
|
|
Name: Keeren Shah
|
|
|
|
|
Title: Finance Director
|
|
|
|
|
|
|
Actavia Life Sciences (CE) (USOTC:RASP)
Historical Stock Chart
From Dec 2024 to Jan 2025
Actavia Life Sciences (CE) (USOTC:RASP)
Historical Stock Chart
From Jan 2024 to Jan 2025
